Cargando…

AKT1(low) quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer

BACKGROUND: Absence of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) correlates with poor long-term survival in patients with triple negative breast cancer (TNBC). These incomplete treatment responses are likely determined by mechanisms that enable cancer cells to resist bein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kabraji, Sheheryar, Solé, Xavier, Huang, Ying, Bango, Clyde, Bowden, Michaela, Bardia, Aditya, Sgroi, Dennis, Loda, Massimo, Ramaswamy, Sridhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540189/ https://www.ncbi.nlm.nih.gov/pubmed/28764807 http://dx.doi.org/10.1186/s13058-017-0877-7

Ejemplares similares

AKT1(low) quiescent cancer cells in ductal carcinoma in situ of the breast
por: Kabraji, Sheheryar, et al.
Publicado: (2019)

THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES
por: Ni, Jing, et al.
Publicado: (2019)

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
por: Vidula, Neelima, et al.
Publicado: (2017)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method
por: Liu, Zongming, et al.
Publicado: (2019)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

The secret life of quiescent cancer stem cells
por: Zeuner, Ann
Publicado: (2014)

Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer
por: Tyekucheva, Svitlana, et al.
Publicado: (2017)

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
por: Amos, Keith D., et al.
Publicado: (2012)

Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
por: Fitzpatrick, Amanda, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
por: Shi, Zhen, et al.
Publicado: (2022)

Systems-Level Modeling of Cancer-Fibroblast Interaction
por: Wadlow, Raymond C., et al.
Publicado: (2009)

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2013)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer
por: Xiao, Yan, et al.
Publicado: (2022)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
por: Silva, Diogo, et al.
Publicado: (2022)

Iron chelators target both proliferating and quiescent cancer cells
por: Fryknäs, Mårten, et al.
Publicado: (2016)

Towards a Framework for Better Understanding of Quiescent Cancer Cells
por: Nik Nabil, Wan Najbah, et al.
Publicado: (2021)

NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer
por: Zhou, Lei, et al.
Publicado: (2020)

Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: a single institution study
por: Sridhar, Nithya, et al.
Publicado: (2022)

Differentiated cytoplasmic granule formation in quiescent and non-quiescent cells upon chronological aging
por: Lee, Hsin-Yi, et al.
Publicado: (2016)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer
por: Han, Xu, et al.
Publicado: (2023)

Modeling Selective Elimination of Quiescent Cancer Cells from Bone Marrow
por: Cavnar, Stephen P., et al.
Publicado: (2015)

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
por: Karlsson, Henning, et al.
Publicado: (2022)

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
por: Parsons, Heather A., et al.
Publicado: (2023)

Caloric restriction causes a distinct reorganization of the lipidome in quiescent and non-quiescent cells of budding yeast
por: Mohammad, Karamat, et al.
Publicado: (2021)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p4spd4nll17g2vnule5oe2b774